Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review

被引:10
作者
Patel, Priya [1 ]
Olteanu, Ana [2 ]
Cabral, Sandra [1 ]
Santesso, Nancy [3 ]
Robinson, Paula D. [1 ]
Dupuis, L. Lee [2 ,4 ,5 ]
机构
[1] Pediat Oncol Grp Ontario, Toronto, ON, Canada
[2] Hosp Sick Children, Child Hlth Evaluat Sci Res Inst, Toronto, ON, Canada
[3] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[4] Univ Toronto, Hosp Sick Children, Dept Pharm, Toronto, ON, Canada
[5] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
关键词
chemotherapy-induced nausea and vomiting; dexamethasone; pediatric oncology; supportive care; INDUCED NAUSEA; DOUBLE-BLIND; PLUS DEXAMETHASONE; EMETOGENIC CHEMOTHERAPY; ADOLESCENT PATIENTS; CHILDREN; CANCER; PLACEBO; EMESIS; ONDANSETRON;
D O I
10.1002/pbc.28716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A systematic review was undertaken to describe dexamethasone doses studied for chemotherapy-induced vomiting (CIV) prophylaxis in pediatric patients and their effects on achieving complete acute CIV control. No dose-finding studies were identified. However, 16 studies assessing pediatric patients who received dexamethasone were included and classified according to the emetogenicity of chemotherapy administered. Eight different total daily dexamethasone doses were administered to patients on day 1 of highly emetogenic chemotherapy: three in conjunction with aprepitant/fosaprepitant plus a 5HT(3)antagonist and five in conjunction with a 5HT(3)antagonist. Five different total daily dexamethasone doses were administered in conjunction with a 5HT(3)antagonist to patients on day 1 of moderately emetogenic chemotherapy. Due to the heterogeneity of studies identified, meta-analysis was not possible. The optimal dexamethasone dose to control acute CIV and to minimize harms in pediatric patients remains uncertain. This is a key area for future research.
引用
收藏
页数:9
相关论文
共 44 条
[1]   RANDOMIZED DOUBLE-BLIND CROSSOVER ONDANSETRON-DEXAMETHASONE VERSUS ONDANSETRON-PLACEBO STUDY FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC-PATIENTS WITH MALIGNANCIES [J].
ALVAREZ, O ;
FREEMAN, A ;
BEDROS, A ;
CALL, SK ;
VOLSCH, J ;
KALBERMATTER, O ;
HALVERSON, J ;
CONVY, L ;
COOK, L ;
MICK, K ;
ZIMMERMAN, G .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1995, 17 (02) :145-150
[2]  
[Anonymous], 1998, J Clin Oncol, V16, P2937
[3]   Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: What is the evidence? [J].
Antonarakis, ES ;
Evans, JL ;
Heard, GF ;
Noonan, LM ;
Pizer, BL ;
Hain, RDW .
PEDIATRIC BLOOD & CANCER, 2004, 43 (06) :651-658
[4]   Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial [J].
Bakhshi, Sameer ;
Batra, Atul ;
Biswas, Bivas ;
Dhawan, Deepa ;
Paul, Reeja ;
Sreenivas, Vishnubhatla .
SUPPORTIVE CARE IN CANCER, 2015, 23 (11) :3229-3237
[5]  
Basade M, 1996, Indian Pediatr, V33, P321
[6]   Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: A Prospective, Observational Study [J].
Bodge, Megan ;
Shillingburg, Alexandra ;
Paul, Stephan ;
Biondo, Lisa .
PEDIATRIC BLOOD & CANCER, 2014, 61 (06) :1111-1113
[7]   Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma [J].
Carroll, Catherine ;
Clinton, Frieda ;
Smith, Aisling ;
Fox, Aine ;
Capra, Michael ;
Pears, Jane ;
Owens, Cormac .
PEDIATRIC BLOOD & CANCER, 2018, 65 (12)
[8]   RANDOMIZED COMPARISON OF ONDANSETRON AND METOCLOPRAMIDE PLUS DEXAMETHASONE FOR CHEMOTHERAPY-INDUCED EMESIS [J].
DICK, GS ;
MELLER, ST ;
PINKERTON, CR .
ARCHIVES OF DISEASE IN CHILDHOOD, 1995, 73 (03) :243-245
[9]  
Dupuis LL, 2018, PEDIATR BLOOD CANCER, V65, pS33
[10]   2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children [J].
Dupuis, L. Lee ;
Sung, Lillian ;
Molassiotis, Alexander ;
Orsey, Andrea D. ;
Tissing, Wim ;
van de Wetering, Marianne .
SUPPORTIVE CARE IN CANCER, 2017, 25 (01) :323-331